FSD Pharma

FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches

Source: FSD Pharma Published on 2021-05-12

FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy

Source: FSD Pharma Published on 2021-05-10

FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company’s Nominees to the Board Using Only the BLUE Proxy

Source: FSD Pharma Published on 2021-05-05

FSD Pharma Announces Appointment of Interim Chief Financial Officer

Source: FSD Pharma Published on 2021-05-05

FSD Pharma Issues Important Message to Shareholders and Response to Dissident Circular

Source: FSD Pharma Published on 2021-05-03

Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy

Source: FSD Pharma Published on 2021-04-26

FSD Pharma Files Proxy Materials and Sends Letter to Shareholders

Source: FSD Pharma Published on 2021-04-23

FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting

Source: FSD Pharma Published on 2021-04-05

FSD Pharma Commences Proceedings Against Dissident Shareholders

Source: FSD Pharma Published on 2021-03-31

FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats

Source: FSD Pharma Published on 2021-03-16

Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares

Source: FSD Pharma Published on 2021-03-08

FSD Pharma Announces US$20M At-The-Market Offering

Source: FSD Pharma Published on 2021-02-11

FSD Provides Corporate Update

Source: FSD Pharma Published on 2021-01-26

FSD Pharma Sets Date for Annual Meeting

Source: FSD Pharma Published on 2021-01-22

FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19

Source: FSD Pharma Published on 2020-12-15

FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Source: FSD Pharma Published on 2020-11-12

FSD Pharma Announces Settlement of Class Action Proceeding

Source: FSD Pharma Published on 2020-10-29

FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering

Source: FSD Pharma Published on 2020-10-21

FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering

Source: FSD Pharma Published on 2020-10-16

FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

Source: FSD Pharma Published on 2020-10-05

FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

Source: FSD Pharma Published on 2020-09-28

FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19

Source: FSD Pharma Published on 2020-08-31

FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19

Source: FSD Pharma Published on 2020-08-31

HUGE.CN: FSD Pharma’s FSD’s Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA.

Source: FSD Pharma Published on 2020-08-20

FSD Pharma Reports Second Quarter 2020 Financial Results

Source: FSD Pharma Published on 2020-08-07

FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors

Source: FSD Pharma Published on 2020-08-06

FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video

Source: FSD Pharma Published on 2020-07-31

FSD Pharma Inc. Announces US$10 Million Registered Direct Offering

Source: FSD Pharma Published on 2020-07-31

FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.

Source: FSD Pharma Published on 2020-07-30

FSD Pharma Announces US$20M At-The-Market Offering

Source: FSD Pharma Published on 2020-07-13

InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com

Source: FSD Pharma Published on 2020-06-23

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Source: FSD Pharma Published on 2020-06-22

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

Source: FSD Pharma Published on 2020-06-09

HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients

Source: FSD Pharma Published on 2020-06-09

FSD Pharma Inc. Announces C$10.125 Million Private Placement

Source: FSD Pharma Published on 2020-06-04

Covid Report: Small Biotech Triples On Plans To Test A Coronavirus Drug